We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Alternatives to Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections.
- Authors
Micek, Scott T.
- Abstract
Vancomycin remains the reference standard for the treatment of systemic infection caused by methicillinresistant Staphylococcus aureus (MRSA). However, as a result of limited tissue distribution, as well as the emergence of isolates with reduced susceptibility and in vitro resistance to vancomycin, the need for alternative therapies that target MRSA has become apparent. New treatment options for invasive MRSA infections include linezolid, daptomycin, tigecycline, and quinupristin/dalfopristin. Additionally, a number of new anti-MRSA compounds are in development, including novel glycopeptides (dalbavancin, telavancin, and oritavancin), ceftobiprole, and iclaprim. The present article will review clinical issues surrounding the newly marketed and investigational agents with activity against MRSA.
- Subjects
VANCOMYCIN resistance; VANCOMYCIN; STAPHYLOCOCCUS aureus; STAPHYLOCOCCUS aureus infections; DALFOPRISTIN; STREPTOGRAMINS; DRUG resistance in microorganisms; MULTIDRUG-resistant tuberculosis; STAPHYLOCOCCAL diseases; BACTERIAL diseases
- Publication
Clinical Infectious Diseases, 2007, Vol 45, pS184
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1086/519471